RRD-251 was developed as an antineoplastic drug that abolishes the phosphorylation of pRb by specifically disrupting the physical interaction between Raf-1 and pRb, and this has been shown to increase the apoptosis of tumor cells both in vitro and in vivo [20]. Here, RAF1 is linked to neoplasm.